Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-01-18 Sale |
2024-01-19 7:32 pm |
AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director |
100,000 | $19.11 | $1,911,410 | 504,079 (Indirect Direct) |
View |
| 2024-01-16 Sale |
2024-01-18 6:19 pm |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director |
100,000 | $19.65 | $1,965,000 | 377,542 (Indirect) |
View |
| 2024-01-16 Sale |
2024-01-18 6:18 pm |
AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. Adjuvant Capital GP L.P. Adjuvant Capital Management LLC 10% Owner |
100,000 | $19.65 | $1,965,000 | 2,373,500 (Indirect Direct) |
View |
| 2024-01-12 Sale |
2024-01-17 5:03 pm |
AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director |
1,425 | $21.91 | $31,229 | 485,073 (Indirect) |
View |
| 2024-01-10 Sale |
2024-01-12 5:08 pm |
AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director |
3,669 | $21.93 | $80,443 | 485,792 (Indirect) |
View |
| 2024-01-09 Sale |
2024-01-11 7:59 pm |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
7,417 | $20.14 | $149,367 | 78,614 (Direct) |
View |
| 2024-01-02 Sale |
2024-01-04 6:06 pm |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
2,583 | $20.12 | $51,967 | 54,199 (Direct) |
View |
| 2024-01-02 Sale |
2024-01-04 6:05 pm |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
2,777 | $20.09 | $55,802 | 1,212,012 (Indirect Direct) |
View |
| 2023-11-14 Sale |
2023-11-16 6:59 pm |
AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. Adjuvant Capital GP L.P. Adjuvant Capital Management LLC 10% Owner |
1,810 | $16.15 | $29,224 | 2,473,500 (Indirect Direct) |
View |
| 2023-11-14 Sale |
2023-11-16 6:57 pm |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director 10% Owner |
1,810 | $16.15 | $29,224 | 393,449 (Indirect) |
View |
| 2023-09-29 Sale |
2023-10-03 7:21 pm |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director 10% Owner |
104,773 | $16.27 | $1,704,513 | 393,737 (Indirect) |
View |
| 2023-09-29 Sale |
2023-10-03 7:13 pm |
AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. Adjuvant Capital GP L.P. Adjuvant Capital Management LLC 10% Owner |
104,773 | $16.27 | $1,704,513 | 2,475,310 (Indirect Direct) |
View |
| 2023-09-27 Sale |
2023-09-29 5:41 pm |
AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. Adjuvant Capital GP L.P. Adjuvant Capital Management LLC 10% Owner |
9,357 | $16.11 | $150,708 | 2,580,083 (Indirect Direct) |
View |
| 2023-09-27 Sale |
2023-09-29 5:40 pm |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director 10% Owner |
9,357 | $16.11 | $150,708 | 410,403 (Indirect) |
View |
| 2023-09-13 Sale |
2023-09-15 5:40 pm |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director 10% Owner |
400 | $16 | $6,400 | 411,893 (Indirect) |
View |
| 2023-09-13 Sale |
2023-09-15 5:17 pm |
AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. Adjuvant Capital GP L.P. Adjuvant Capital Management LLC 10% Owner |
400 | $16 | $6,400 | 2,589,440 (Indirect Direct) |
View |
| 2023-09-06 Sale |
2023-09-08 4:59 pm |
AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. Adjuvant Capital GP L.P. Adjuvant Capital Management LLC 10% Owner |
7,140 | $16.03 | $114,484 | 2,589,840 (Indirect Direct) |
View |
| 2023-09-06 Sale |
2023-09-08 4:57 pm |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director 10% Owner |
7,140 | $16.03 | $114,484 | 411,957 (Indirect) |
View |
| 2023-08-23 Sale |
2023-08-25 4:31 pm |
AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. Adjuvant Capital GP L.P. Adjuvant Capital Management LLC 10% Owner |
400 | $16 | $6,400 | 2,596,980 (Indirect Direct) |
View |
| 2023-08-23 Sale |
2023-08-25 4:30 pm |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director 10% Owner |
400 | $16 | $6,400 | 413,092 (Indirect) |
View |
| 2023-08-18 Purchase |
2023-08-22 5:01 pm |
AN2 Therapeutics Inc. | ANTX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. 10% Owner |
1,777,778 | $9 | $16,000,002 | 5,551,295 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-03-15 Option Award(A) |
2024-03-29 4:18 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Day Lucy Chief Financial Officer |
27,500 | $0 | 30,627 (Direct) |
View |
| 2024-03-15 Option Award(A) |
2024-03-29 4:18 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Eizen Joshua M Chief Legal Officer |
30,000 | $0 | 32,447 (Direct) |
View |
| 2024-03-15 Option Award(A) |
2024-03-29 4:17 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
30,000 | $0 | 31,914 (Direct) |
View |
| 2024-03-15 Option Award(A) |
2024-03-29 4:16 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Chanda Sanjay Chief Development Officer |
27,500 | $0 | 28,235 (Direct) |
View |
| 2024-03-15 Option Award(A) |
2024-03-29 4:16 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
99,000 | $0 | 101,130 (Direct) |
View |
| 2024-03-15 Option Award |
2024-03-18 7:29 pm |
N/A 2034-03-14 |
AN2 Therapeutics Inc. | ANTX | Day Lucy Chief Financial Officer |
82,500 | $0 | 85,627 (Direct) |
View |
| 2024-03-15 Option Award |
2024-03-18 7:28 pm |
N/A 2034-03-14 |
AN2 Therapeutics Inc. | ANTX | Eizen Joshua M Chief Legal Officer |
90,000 | $0 | 92,447 (Direct) |
View |
| 2024-03-15 Option Award |
2024-03-18 7:28 pm |
N/A 2034-03-14 |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
90,000 | $0 | 91,914 (Direct) |
View |
| 2024-03-15 Option Award |
2024-03-18 7:27 pm |
N/A 2034-03-14 |
AN2 Therapeutics Inc. | ANTX | Chanda Sanjay Chief Development Officer |
82,500 | $0 | 83,235 (Direct) |
View |
| 2024-03-15 Option Award |
2024-03-18 7:27 pm |
N/A 2034-03-14 |
AN2 Therapeutics Inc. | ANTX | Eckburg Paul Chief Medical Officer |
90,000 | $0 | 111,416 (Direct) |
View |
| 2024-03-15 Option Award |
2024-03-18 7:26 pm |
N/A 2034-03-14 |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
297,000 | $0 | 1,509,012 (Direct) |
View |
| 2024-01-09 Exercise |
2024-01-11 7:59 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
2,417 | $0.42 | 78,614 (Direct) |
View |
| 2024-01-09 Exercise |
2024-01-11 7:59 pm |
N/A 2030-01-22 |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
7,417 | $0 | 78,614 (Direct) |
View |
| 2024-01-09 Exercise |
2024-01-11 7:59 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
5,000 | $6.6 | 78,614 (Direct) |
View |
| 2024-01-02 Exercise |
2024-01-04 6:06 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
2,583 | $0.42 | 54,199 (Direct) |
View |
| 2024-01-02 Exercise |
2024-01-04 6:06 pm |
N/A 2030-01-22 |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
2,583 | $0 | 54,199 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 9:04 pm |
N/A 2033-06-06 |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director 10% Owner |
23,742 | $0 | 23,742 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 8:57 pm |
N/A 2033-06-06 |
AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director |
23,742 | $0 | 23,742 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 8:54 pm |
N/A 2033-06-06 |
AN2 Therapeutics Inc. | ANTX | FitzPatrick Margaret M Director |
23,742 | $0 | 23,742 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 8:49 pm |
N/A 2033-06-06 |
AN2 Therapeutics Inc. | ANTX | Wong Stephanie Director |
23,742 | $0 | 23,742 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 8:44 pm |
N/A 2033-06-06 |
AN2 Therapeutics Inc. | ANTX | Marks Gilbert Lynn Director |
23,742 | $0 | 23,742 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 8:42 pm |
N/A 2033-06-06 |
AN2 Therapeutics Inc. | ANTX | Martin Patricia A. Director |
23,742 | $0 | 23,742 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 8:37 pm |
N/A 2033-06-06 |
AN2 Therapeutics Inc. | ANTX | Spigelman Melvin K Director |
23,742 | $0 | 23,742 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 8:33 pm |
N/A 2033-06-06 |
AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director |
23,742 | $0 | 23,742 (Direct) |
View |